23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
19:56 , Apr 10, 2019 |  BC Extra  |  Financial News

Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

At least four biotechs announced venture rounds this week, including rare mineralization disorders play Inozyme and three companies backed by Asian investors. Inozyme Pharma Inc. (Boston, Mass.) raised $67 million in a series A2 round...
18:56 , Jan 26, 2018 |  BioCentury  |  Emerging Company Profile

Quenching calcium

Inozyme Pharma Inc. is developing an enzyme replacement therapy that could be useful for a broad range of calcification disorders, and provide better efficacy and safety than off-label options. Its sole asset, INZ-701, is a...
19:46 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Inozyme raises $49M series A

On Nov. 15, Inozyme Pharma Inc. (Cambridge, Mass.) raised $49 million in a series A round led by Longitude Capital, with participation from New Enterprise Associates, Novo Ventures and Sanofi Ventures. The newco, which spun...
18:53 , Nov 17, 2017 |  BioCentury  |  Finance

Starting rare

Inozyme Pharma Inc. plans to use its $49 million series A round to demonstrate human proof of concept for its lead candidate in a pair of rare calcification disorders. But the newco and its lead...
12:02 , Nov 15, 2017 |  BC Extra  |  Financial News

Inozyme raises $49M series A

Inozyme Pharma Inc. (Cambridge, Mass.) raised $49 million in a series A round led by Longitude Capital, with participation from New Enterprise Associates, Novo Ventures and Sanofi Ventures. The newco, which spun out of Yale...
20:44 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Mouse studies suggest inhibiting ENPP1 could help treat post-injury cardiac calcification. In a mouse model of cryogenically induced cardiac injury, two ENPP1 inhibitor tool compounds decreased calcification of heart muscle tissue compared with...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ectonucleotide pyrophosphates / phosphodiesterase 1 (ENPP1)

Cardiovascular disease INDICATION: Cardiovascular Mouse studies identified an ENPP1 fusion protein that could help treat generalized arterial calcification of infancy (GACI), which is associated with loss-of-function mutations in ENPP1. In an ENPP1-mutant mouse model of...
07:00 , May 18, 2015 |  BioCentury  |  Strategy

Alexion executes

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc .'s biggest move to date under a four-year-old plan to diversify its portfolio. The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal...